Drug Approval | November 22, 2021
European Commission approves Roche’s Gavreto
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
It is used for the treatment of advanced colorectal and gastric cancer
Taluka level transplant centre will add convenience to patients from rural areas
Nelarabine is in a class of medications called antimetabolites
The interim data combines three mRNAs into one therapy injected directly into the tumour
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
The centre has an initial capacity of 500 FTEs
Expertise in exosomes isolation and characterization will drive innovation in this field
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
Subscribe To Our Newsletter & Stay Updated
